Automated flow-through synthesis of heterocyclic thioethers

Journal of Combinatorial Chemistry

Volumn 6, Issue 4, 2004, Pages 584-595

  Jönsson, Daniel ^a   Warrington, Brian H ^a   Ladlow, Mark ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHER DERIVATIVE; RESIN; THIOL DERIVATIVE;

ARTICLE; AUTOMATION; CYCLIZATION; FLOW KINETICS; PURIFICATION; QUANTUM YIELD; RADIATION DETECTION; REACTOR; ROBOTICS; SCREENING; SYNTHESIS; ULTRAVIOLET SPECTROSCOPY;

EID: 4143050396     PISSN: 15204766     EISSN: None     Source Type: Journal    
DOI: 10.1021/cc0499486     Document Type: Article

References (48)

1. (a) Gordon, E. M.; Gallop, M. A.; Patel, D. V. Acc. Chem. Res. 1996, 29, 144.
2. (b) Li, J.; Murray, C. W.; Waszkowycz, B.; Young, S. C. Drug Discovery Today 1998, 3, 105.
3. (c) Kenny, B. A.; Bushfield, M.; Parry-Smith, D. J.; Fogarty, S.; Treherne J. M. Prog. Drug Res. 1998, 51, 245.
4. (d) Golebiowski, A.; Klopfenstein, S. R.; Portlock, D. E. Curr. Opin. Chem. Biol. 2001, 5, 273.
5. (a) Yoshida, J.; Itami, K. Chem. Rev. 2002, 102, 3693.
6. (b) Ganesan, A. Drug Discovery Today 2002, 7, 47.
7. (c) Dörwald, F. Z. Organic Synthesis on Solid Phase; Wiley-VCH: Weinheim, 2000.
8. (d) Obrecht, D.; Villalgordo, J. M. Solid-Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight Compound Libraries; Pergamon: Oxford, 1998.
9. (a) Drewry, D. H.; Coe, D. M.; Poon, S. Med. Res. Rev. 1999, 19, 97.
10. (b) Ley S. V.; Baxendale I. R.; Bream, R. N.; Jackson, P. S.; Leach, A. G.; Longbottom, D. A.; Nesi, M.; Scott, J. S.; Storer, R. I.; Taylor, S. J. J. Chem. Soc., Perkin Trans. 1 2000, 3815.
11. (c) Kirschning A.; Monenschein, H.; Wittenberg, R.; Angew. Chem., Int. Ed. 2001, 40, 650.
12. (d) Flynn, D. L.; Berk, S. C.; Makara, G. M. Curr. Opin. Drug Discovery Dev. 2002, 5, 580.
13. (e) Ley, S. V.; Baxendale, I. R. Nat. Rev. Drug Discovery 2002, 1, 573.
14. For example, see: (a) Carpanone: Baxendale, I. R.; Lee, A.-L.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1, 2002, 1850. (b) Plicamine: Baxendale, I. R.; Ley, S. V.; Nessi M.; Piutti, C. Tetrahedron 2002, 6285. (c) Epothilone: Storer, R. I.; Takemoto, T.; Jackson, P. S.; Ley, S. V. Angew. Chem., Int. Ed. 2003, 42, 2521. (d) Glycoconjugates: Jaunzems, J.; Hofer, E.; Jesberger, M.; Sourkouni-Argirusi, G.; Kirschning, A. Angew. Chem., Int. Ed. 2003, 42, 1166.
15. For example, see: (a) Carpanone: Baxendale, I. R.; Lee, A.-L.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1, 2002, 1850. (b) Plicamine: Baxendale, I. R.; Ley, S. V.; Nessi M.; Piutti, C. Tetrahedron 2002, 6285. (c) Epothilone: Storer, R. I.; Takemoto, T.; Jackson, P. S.; Ley, S. V. Angew. Chem., Int. Ed. 2003, 42, 2521. (d) Glycoconjugates: Jaunzems, J.; Hofer, E.; Jesberger, M.; Sourkouni-Argirusi, G.; Kirschning, A. Angew. Chem., Int. Ed. 2003, 42, 1166.
16. For example, see: (a) Carpanone: Baxendale, I. R.; Lee, A.-L.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1, 2002, 1850. (b) Plicamine: Baxendale, I. R.; Ley, S. V.; Nessi M.; Piutti, C. Tetrahedron 2002, 6285. (c) Epothilone: Storer, R. I.; Takemoto, T.; Jackson, P. S.; Ley, S. V. Angew. Chem., Int. Ed. 2003, 42, 2521. (d) Glycoconjugates: Jaunzems, J.; Hofer, E.; Jesberger, M.; Sourkouni-Argirusi, G.; Kirschning, A. Angew. Chem., Int. Ed. 2003, 42, 1166.
17. For example, see: (a) Carpanone: Baxendale, I. R.; Lee, A.-L.; Ley, S. V. J. Chem. Soc., Perkin Trans. 1, 2002, 1850. (b) Plicamine: Baxendale, I. R.; Ley, S. V.; Nessi M.; Piutti, C. Tetrahedron 2002, 6285. (c) Epothilone: Storer, R. I.; Takemoto, T.; Jackson, P. S.; Ley, S. V. Angew. Chem., Int. Ed. 2003, 42, 2521. (d) Glycoconjugates: Jaunzems, J.; Hofer, E.; Jesberger, M.; Sourkouni-Argirusi, G.; Kirschning, A. Angew. Chem., Int. Ed. 2003, 42, 1166.
18. (a) Caldarelli, M.; Habermann J.; Ley, S. V. Bioorg. Med. Chem. Lett. 1999, 9, 2049.
19. (b) Lee A.; Ellman, J. A. Org. Lett. 2001, 3, 3707.
20. (c) Baxendale I. R.; Ley, S. V. Bioorg. Med. Chem. Lett. 2000, 10, 1983.
21. (d) Vickerstaffe, E.; Warrington, B. H.; Ladlow, M.; Ley, S. V. Org. Biomol. Chem. 2003, 1, 2419.
22. Hafez, A. M.; Taggi, A. E.; Dudding, T.; Letcka, T. J. Am. Chem. Soc. 2001, 123, 10853.
23. Tundo P. Continuous Flow Methods in Organic Synthesis; Ellis Horwood: New York, 1991.
24. (a) Hafez, A. M.; Taggi, A. E.; Lectka, T. Chem. - Eur. J. 2002, 8 (18), 4114.
25. (b) Hodge, P. Curr. Opin. Chem. Biol. 2003, 7, 362.
26. (c) Jas, G.; Kirschning, A. Chem. - Eur. J. 2003, 9, 5708.
27. For an example of how this may be achieved by a divergent solid-phase synthesis, see: Purandare, A. V.; Aiming, G.; Poss, M. A. Tetrahedron Lett. 2002, 43, 3903.
28. (a) Thompson, L. A. Curr. Opin. Chem. Biol. 2000, 4, 324.
29. (b) Flynn, D. L. Med. Res. Rev. 1999, 19, 408.
30. (c) Kirschning, A.; Monenschein, H.; Wittenberg, R. Chem. - Eur. J. 2000, 6, 4445.
31. (d) Kulkarni, B. A.; Ganesan, A. Angew. Chem., Int. Ed. Engl. 1997, 36, 2454.
32. -1, see: Schwesinger, R. Chimia 1985, 39, 269. For an example of the use of this base in alkylation of acidic heterocycles, see: Xu, W.; Mohan, R.; Morrissey, M. M. Bioorg. Med. Chem. Lett. 1998, 8, 1089.
33. -1, see: Schwesinger, R. Chimia 1985, 39, 269. For an example of the use of this base in alkylation of acidic heterocycles, see: Xu, W.; Mohan, R.; Morrissey, M. M. Bioorg. Med. Chem. Lett. 1998, 8, 1089.
34. -1: (a) Morrissey, M. M.; Mohan, R.; Xu, W. Tetrahedron Lett. 1997, 38, 7337. (b) Organ, M. G.; Dixon, C. E. Biotech. Bioeng. Comb. Chem. 2000, 71, 71.
35. -1: (a) Morrissey, M. M.; Mohan, R.; Xu, W. Tetrahedron Lett. 1997, 38, 7337. (b) Organ, M. G.; Dixon, C. E. Biotech. Bioeng. Comb. Chem. 2000, 71, 71.
36. Graybill, T. L.; Thomas, S.; Wang, M. A. Tetrahedron Lett. 2002, 43, 5305.
37. (b) Adams, G. L.; Graybill, T. L.; Sanchez, V. W.; Magaard, G. B.; Rivero, R. A. Tetrahedron Lett. 2003, 44, 5041.
38. (a) Peters, E. C.; Svec, F.; Fréchet, J. M. J. Adv. Mater. 1999, 11, 1169.
39. (b) Hird, N.; Hughes, I.; Hunter, D.; Morrison, M. G. J. T.; Stevenson, L. Tetrahedron 1999, 55, 9575.
40. (c) Tripp, J. A.; Svec, F.; Fréchet, J. M. J. J. Comb. Chem. 2001, 3, 216.
41. (d) Kirschning, A.; Altwicker, C.; Dräger, G.; Harders, J.; Hoffman, N.; Hoffman, U.; Schönfield, W.; Solodenko, W.; Kunz, U. Angew. Chem., Int. Ed. Engl. 2001, 113, 4118.
42. (e) Sundmacher, K.; Künne, H.; Kunz, U. Chem. Ing. Technol. 1998, 70, 267.
43. 5- catenadi(phosphazene); 1.0 M solution in hexane, see: Schwesinger, R.; Schlemper, H. Angew. Chem. 1987, 99, 1212.
44. Commercial Gilson HPLC modules were used to construct the flow-through synthesiser, and the device was controlled using Unipoint v3.3 software (www.Gilson.com).
45. Although in principle, slope detection can also be used to control the fraction collector, this method was found to be unreliable in this case.
46. In principle, according to the flow-through paradigm we have exploited, compounds with high purities should also be associated with high isolated yields. Lower yields would be expected to correlate to products that were contaminated with unreacted alkylating agent, particularly for nonvolatile electrophiles. However, this was not observed in practice, and all purities were uniformly high. The lower yields are most likely to be attributable to nonoptimal sample collection in some cases, which arises as a consequence of using a generic set of parameters to trigger the fraction collector.
47. (a) Andrews, S. P.; Ladlow, M. J. Org. Chem. 2003, 68, 5525.
48. (b) Pan, P.-C.; Sun, C.-M. Bioorg. Med. Chem. Lett. 1999, 9, 1537.